This is an aggregated industry headline. Read the full story at BioPharma Dive →
Celcuity gains FDA approval for closely watched breast cancer drug
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug's prescribing information surprised some analysts, too.
By BioPharma Dive
· Jul 15, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Merck & Co.'s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent fo…
The WeekFierceBiotech ↗
Vogenx has joined the growing queue for the Nasdaq, as the metabolic biotech eyes an IPO to fund its SGLT1 inh…
The WeekBriefing
Biogen reported mid-stage trial data showing its Alzheimer’s drug slowed cognitive decline at rates similar to…